{"id":"W4406702927","doi":"10.1093/ecco-jcc/jjae190.0762","title":"P0588 Efficacy and health-related quality of life associated with second-line vedolizumab after one prior first-line anti-tumour necrosis factor treatment in patients with active ulcerative colitis: A meta-analysis of the GEMINI-1 and VISIBLE-1 trials","year":2025,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Takeda (Canada)","funders":"","keywords":"Vedolizumab; Medicine; Ulcerative colitis; Internal medicine; Gastroenterology; Quality of life (healthcare); First line; Colitis; Inflammatory bowel disease; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009231281,0.002201944,0.01076246,0.002187467,0.0004450969,0.00273955,0.001453708,0.00194865,0.002549555],"category_scores_gemma":[0.01242867,0.001134504,0.03817545,0.002803856,0.000619425,0.001171336,0.001038686,0.002459889,0.0002346691],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001235847,"about_ca_system_score_gemma":0.000725213,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003207478,"about_ca_topic_score_gemma":0.004632819,"domain_scores_codex":[0.9920318,0.004781923,0.001191589,0.001220046,0.0005336208,0.000241013],"domain_scores_gemma":[0.9905668,0.00627791,0.002004723,0.0004862023,0.0004163296,0.0002480239],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.02062139,0.00005850874,0.009192442,0.02632246,0.9375102,0.00007257737,0.00003148385,0.0008080377,0.0003429655,0.00006415862,0.0003279543,0.004647748],"study_design_scores_gemma":[0.004431004,0.0007818185,0.01127461,0.001361314,0.9804623,0.000082816,0.00002534645,0.0005722523,0.0001659906,0.0001812907,0.0006388623,0.00002234993],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.1243565,0.8698988,0.001378451,0.0005477191,0.0004438258,0.0002897166,0.002040392,0.00008100108,0.0009635041],"genre_scores_gemma":[0.9332537,0.06248506,0.001236957,0.0006971805,0.0002442862,0.0003604188,0.001310569,0.00003370049,0.000378016],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.01076246,"threshold_uncertainty_score":0.04882026,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0397964947726718,"score_gpt":0.3081015953067536,"score_spread":0.2683051005340819,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}